 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NHS GP Practice - Dr. John Pillinger, Dr. Reginald Odbert, Dr. Stephen Collins, Dr. Naveed Sami, Dr Anne Lloyd-Thomas, Dr Lucy Godwin and Dr Zelda Cheng.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highcliffe Medical Centre & The Mudeford Surgery
NHS treatment available from both male and female doctors offering many specialised services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Protection against pneumococcal pneumonia.
The surgery is offering a single vaccination against this form of pneumonia to everyone over 65 years of age and to all people with asthma, chest disease, diabetes and others who are at increased risk from this condition.
We recommend people arrange to have their vaccination either during a routine visit to the nurse or doctor; or to make an appointment with one of the nurses requesting a pneumovax injection. This vaccination provides protection for 10 years for most people.
|
|
|
|
|
|
|
|
|
|
Pneumovax is a vaccine designed to treat
Pneumonia
Bacteremia
Meningitis
Otitis Media
Pneumococcal Infection (the world's leading cause of death)
Pneumovax is an important vaccine prophylaxis against pneumococcal disease because in many parts of the world, pneumococcal isolates are becoming increasingly resistant to penicillin.
Despite appropriate antimicrobial therapy and intensive medical care, these penicillin-resistant pneumococci are also becoming increasingly resistant to other antimicrobial drugs.
|
|
|
|
|
|
|
|
|
|
|
|
How common is invasive pneumococcal disease?
Pneumococcal pneumonia is estimated to affect 1 in 1000 adults each year and to have a mortality of 10-20% [World Health Organization, 1999].
|
|
|
|
|
|
|
|
|
|
|
|
|
How does vaccination with pneumococcal vaccine lead to immunity?
Pneumococcal vaccines use organism products (purified capsular polysaccharide from several strains of Streptococcus pneumoniae) to achieve active immunity.
These organism products produce a protective effect by inducing cell-mediated immunity and serum antibodies.
The primary response occurs after the first administration of organism products to a person without prior exposure to the antigen. A slow antibody response (predominantly immunoglobulin M) is produced.
The secondary response occurs when further administrations increase the antibody titre (immunoglobulin G) to a higher level.
Most adults will have had some previous exposure to S pneumoniae, and so will develop a good immunoglobulin G antibody response to a single dose of pneumococcal vaccine by the third week following immunization.
Children, however, need a primary series of injections to produce immunity; the number of doses required varies with age.
|
|
|
|
|
|
|
|
|
|